Evolution Of Disease Activity And Biomarkers On And Off Rapamycin In 28 Patients With Autoimmune Lymphoproliferative Syndrome

Evolution Of Disease Activity And Biomarkers On And Off Rapamycin In 28 Patients With Autoimmune Lymphoproliferative Syndrome
This is a Letter to the Editor describing 28 cases of autoimmune lymphoproliferative syndrome (ALPS) treated with rapamycin therapy, addressing first- versus second-line therapy, comprehensive biomarker responses, and the consequences of stopping rapamycin.
Very useful description of a patient cohort treated with rapamycin. Also giving advice on levels of rapamycin that are usually active in this particular cohort.